×




Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version case study is a Harvard Business School (HBR) case study written by Carin-Isabel Knoop, Anthony St. George. The Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version (referred as “Indonesian Novartis” from here on) case study provides evaluation & decision scenario in field of Leadership & Managing People. It also touches upon business topics such as - Value proposition, Currency, International business, Joint ventures, Mergers & acquisitions, Recession.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version Case Study


Jan Eriksson is the country manager of the Indonesian joint venture of Basel-based Novartis (Novartis Indonesia), the world's largest pharmaceutical company, formed by the 1996 merger between Sandoz and Ciba-Geigy. The case describes the actions he has taken since assuming his post in May 1996. He was in the middle of merging the Indonesian operations of Sandoz and Ciba-Geigy when the financial crisis struck Indonesia. He has prepared two plans to deal with the crisis. In January 1996, headquarters had still not approved Erickssons' plans and he needs to decide how to proceed.


Case Authors : Carin-Isabel Knoop, Anthony St. George

Topic : Leadership & Managing People

Related Areas : Currency, International business, Joint ventures, Mergers & acquisitions, Recession




Calculating Net Present Value (NPV) at 6% for Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10007398) -10007398 - -
Year 1 3450061 -6557337 3450061 0.9434 3254775
Year 2 3955976 -2601361 7406037 0.89 3520805
Year 3 3970046 1368685 11376083 0.8396 3333327
Year 4 3223211 4591896 14599294 0.7921 2553085
TOTAL 14599294 12661991




The Net Present Value at 6% discount rate is 2654593

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Profitability Index
3. Internal Rate of Return
4. Net Present Value

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Indonesian Novartis have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Indonesian Novartis shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Leadership & Managing People Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Indonesian Novartis often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Indonesian Novartis needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10007398) -10007398 - -
Year 1 3450061 -6557337 3450061 0.8696 3000053
Year 2 3955976 -2601361 7406037 0.7561 2991286
Year 3 3970046 1368685 11376083 0.6575 2610370
Year 4 3223211 4591896 14599294 0.5718 1842881
TOTAL 10444590


The Net NPV after 4 years is 437192

(10444590 - 10007398 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10007398) -10007398 - -
Year 1 3450061 -6557337 3450061 0.8333 2875051
Year 2 3955976 -2601361 7406037 0.6944 2747206
Year 3 3970046 1368685 11376083 0.5787 2297480
Year 4 3223211 4591896 14599294 0.4823 1554403
TOTAL 9474140


The Net NPV after 4 years is -533258

At 20% discount rate the NPV is negative (9474140 - 10007398 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Indonesian Novartis to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Indonesian Novartis has a NPV value higher than Zero then finance managers at Indonesian Novartis can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Indonesian Novartis, then the stock price of the Indonesian Novartis should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Indonesian Novartis should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What can impact the cash flow of the project.

What will be a multi year spillover effect of various taxation regulations.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version

References & Further Readings

Carin-Isabel Knoop, Anthony St. George (2018), "Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry, Spanish Version Harvard Business Review Case Study. Published by HBR Publications.


PBF Energy SWOT Analysis / TOWS Matrix

Energy , Oil & Gas Operations


Novo Nordisk ADR SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


Embelton Ltd SWOT Analysis / TOWS Matrix

Capital Goods , Constr. - Supplies & Fixtures


Mastercard SWOT Analysis / TOWS Matrix

Financial , Consumer Financial Services


Justplanning SWOT Analysis / TOWS Matrix

Technology , Software & Programming


TOTO SWOT Analysis / TOWS Matrix

Capital Goods , Constr. - Supplies & Fixtures


Acrel SWOT Analysis / TOWS Matrix

Technology , Electronic Instr. & Controls


Investec SWOT Analysis / TOWS Matrix

Financial , Investment Services